A Phase II, Single-Arm, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Idasanutlin Monotherapy In Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Protocol: 
AAAR4907
Phase: 
II

A Phase II, Single-Arm, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Idasanutlin Monotherapy In Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Are you Eligible? (Inclusion Criteria)

1) Subject must be at least 18 years of age.

2) Subjects must have a confirmed diagnosis of polycythemia vera.

3) Subjects must be able to understand and willingly sign a written informed consent form.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States